Get all premium features to the best stock analysis tool

Twist Bioscience Corporation (TWST) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Twist Bioscience Corporation (TWST) Shareholder/Analyst Call Transcript

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in fireside chats at the following upcoming investor conferences. TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 in Boston, MA; fireside chat at 1:50 pm Eastern Time Barclays 28th Annual Global Health.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra's B-Body® bispecific antibody platform (“B-Body platform”), e.

In this podcast, Motley Fool analysts Karl Thiel, Tom King, and Tim Beyers discuss:

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, each designed to address a wide range of sample input, including low input and challenging sample types, to enable clinical research. The Twist TrueAmp Library Prep Kit brings a new level of exceptional performance to Twist's library preparation portfolio, wi.

Twist Bioscience's stock has moved high in recent months, driven by optimism related to AI-enabled drug discovery and MRD testing. Q1 growth was modest, due in large part to an air pocket in demand caused by a large NGS customer. NGS growth is expected to rebound as the year progresses, though, supported by customers ramping up commercial testing.